Every year researchers introduce numerous medications for the treatment of various medical disorders. The following is a partial list of formulations approved for health care provider prescription.

Kynamro™ (mipomersen sodium)

Researchers developed this medication for the decrease of low-density lipoproteins or bad cholesterol. The medication acts by inhibiting the formation of atherogenic lipoproteins, which represent the particles that carry cholesterol through the blood. Kynamro™ gained FDA approval following a 26-week trial performed on 51 subjects. Adverse effects include injection site inflammation and flu-like symptoms, including headaches and nausea.

Nesina® (alogliptin)

This oral medication regulates blood sugar levels by inactivating the incretin hormone GLP-1, a glucagon type peptide-1 and GIP, glucose insulin tropic peptide. Physicians might prescribe the medication in conjunction with diet and exercise to control glucose levels in adults diagnosed with Type 2 diabetes mellitus. Taken as a daily 25-milligram dose, Nesina® gained FDA approval after researchers performed various trials on 1,768 patients. Individuals may experience headache, nasopharyngitis, headache, or an upper respiratory infection while on the medication.

Flublok®

The seasonal influenza vaccine represents a trivalent recombinant inoculation manufactured without eggs or live viruses. The vaccine contains HA proteins from three strains of viruses commonly seen during the flu season. The proteins act as antigens, which provoke an immunity response. Flubok® protects individuals aged 18 through 49 against the type A and B influenza viruses. The FDA approved the vaccine following double-blind studies performed on 4,648 adults. Individuals may experience fatigue, headaches, muscle aches, or injection site reactions from Flubok®.

Uceris™ (budesonide)

Researchers developed this synthetic corticosteroid in an oral, extended release form that slowly dissolves in the intestines as a treatment for mild to moderate ulcerative colitis. Having an enteric coating, Uceris™ comes in 9-milligram tablets that patients take whole one time daily in the morning before eating. The treatment may last for up to eight weeks. The medication obtained FDA approval following double-blind studies on 970 patients. The many adverse effects patients may experience while taking the medication include constipation, flatulence, abdominal distention, headache, nausea, and fatigue.

Stivarga® (regorafenib)

This medication inhibits membranes containing kinases required for cellular function in normal and pathogenic cellular growths that include cancers or tumors. Scientists developed the medication for patients diagnosed with advanced metastatic gastrointestinal tumors previously treated with imatinib mesylate or sunitinib. Physicians prescribe four 40-milligram tablets daily over the course of 21 days every 28 days. Patients continue treatment until experiencing tumor minimization or toxicity. The FDA approved the anti-tumor medication after researchers performed double-blind studies on 199 patients. Adverse effects commonly experienced while taking Stivarga® include fatigue, anorexia, diarrhea, gastrointestinal inflammation, fever, nausea, rash, and weight loss.

Kadcyla™ (ado-trastuzumab emtansine)

The HER-2 targeted antibody developed as an alternative treatment for breast cancer. The medication attaches to HER-2 receptors causing cells to release cytotoxic chemicals that interfere with microscopic tubules contained within the cellular network. Eventually, the cell stops functioning and dies. Oncologists may prescribe the medication for HER-2 metastatic breast cancers previously treated with trastuzumab or taxane. Administered as an intravenous infusion, patients receive Kadcyla™ every three weeks until tumor shrinkage or toxicity occurs. Impressive trials on 991 breast cancer patients gained the medication FDA approval. Possible adverse reactions associated with the anti-tumor medication include constipation, headache, fatigue, and nausea in addition to joint or muscle pain and a diminished number in blood-clotting thrombocytes.

Paul Skagit is a freelance writer who concentrates his efforts on medical research, health education, medical technology, general technology, general science and other relevant topics. Those curious about medical research should click here to view the resources from hudsonrobotics.com.

Image | Source